FrancophonIA/ELRC3.0 huggingface dataset:
English: Following a single subcutaneous injection of fondaparinux 2.5 mg to young healthy subjects, peak plasma concentration (mean Cmax = 0.34 mg/l) is obtained 2 hours post-dosing.
Croatian: Nakon pojedinačne supkutane injekcije fondaparinuksa od 2,5 mg mladim zdravim osobama, vršna koncentracija u plazmi (prosječni Cmax = 0,34 mg/l) postiže se 2 sata nakon primjene doze.
English: In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.
Croatian: U velikoj podskupini bolesnika operiranih zbog tumora (69% svih bolesnika) stopa VTE bila je 4,7% u skupini koja je dobivala fondaparinuks u odnosu na 7,7% u skupini koja je dobivala dalteparin.
English: In the Phase III UA/NSTEMI study, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were headache, chest pain and atrial fibrillation.
Croatian: U studiji faze III u bolesnika s UA/NSTEMI, najčešće prijavljene nuspojave koje nisu bile povezane s krvarenjem (prijavljene u najmanje 1% bolesnika na fondaparinuksu) bile su glavobolja, bol u prsima i fibrilacija atrija.
English: The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97.
Croatian: Primarna mjera ishoda djelotvornosti bila je kombinacija potvrđenih simptomatskih rekurentnih VTE bez smrtnog ishoda, te VTE sa smrtnim ishodom prijavljenih do 97.
English: Prevention of Venous Thromboembolic Events (VTE) in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infectious or inflammatory disease.
Croatian: Prevencija venskih tromboembolijskih događaja (VTE) u odraslih nekirurških bolesnika za koje se procjenjuje da postoji visoki rizik nastanka VTE i koji su nepokretni zbog akutne bolesti, npr. srčane insuficijencije i/ili akutnih respiratornih bolesti i/ili akutnih zaraznih ili upalnih bolesti.
English: The mortality rates were low and similar between the treatments groups with 2 (0.1%) deaths in the fondaparinux group versus 1 (0.1%) death in the placebo group.
Croatian: Stopa smrtnosti je bila niska i slična između ispitivanih skupina, s 2 smrti (0,1%) u fondaparinuks skupini naprama 1 smrti (0,1%) u placebo skupini.
English: Adverse reactions in patients undergoing major orthopaedic surgery of lower limbs and/or abdominal surgery
Croatian: Nuspojave u bolesnika s velikom ortopedskom operacijom na donjim ekstremitetima i/ili abdominalnim kirurškim zahvatom
English: In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding (98.6% to 97.0% in the concentration range from 0.5 to 2 mg/l).
Croatian: In vitro, fondaparinuks se, ovisno o koncentraciji odgovarajuće doze u plazmi, u velikoj mjeri i specifično veže za antitrombinski protein (98,6% do 97,0% u rasponu koncentracije od 0,5 do 2 mg/l).
English: If they do, you must not use Arixtra.
Croatian: U takvim situacijama, ne smijete koristiti lijek Arixtra
English: By Day 9, 1.1% of patients treated with fondaparinux and 1.4% of control patients experienced a severe haemorrhage.
Croatian: Do devetog dana je 1,1% bolesnika liječenih fondaparinuksom i 1,4% bolesnika u kontrolnoj skupini doživjelo veliko krvarenje.
English: In studies versus enoxaparin 40 mg once daily started 12 hours before surgery, major bleeding was observed in 2.8% of fondaparinux patients treated with the recommended dose, compared to 2.6% with enoxaparin.
Croatian: U ispitivanjima fondaparinuksa u usporedbi s 40 mg enoksaparina jednom na dan s početkom 12 sati prije operacije, veliko krvarenje zabilježeno je u 2,8% bolesnika koji su primali preporučenu dozu fondaparinuksa, u odnosu na 2,6% koji su primali enoksaparin.
English: PHARMACEUTICAL FORM AND CONTENTS Solution for injection, 2 pre-filled syringes with an automatic safety system Solution for injection, 7 pre-filled syringes with an automatic safety system Solution for injection, 10 pre-filled syringes with an automatic safety system Solution for injection, 20 pre-filled syringes with an automatic safety system Solution for injection, 2 pre-filled syringes with a manual safety system Solution for injection, 10 pre-filled syringes with a manual safety system Solution for injection, 20 pre-filled syringes with a manual safety system
Croatian: Otopina za injekciju, 2 napunjene štrcaljke sa automatskim sigurnosnim sustavom Otopina za injekciju, 7 napunjenih štrcaljki sa automatskim sigurnosnim sustavom Otopina za injekciju, 10 napunjenih štrcaljki sa automatskim sigurnosnim sustavom Otopina za injekciju, 20 napunjenih štrcaljki sa automatskim sigurnosnim sustavom
English: Alternate the left and right side of the lower abdominal area at each injection.
Croatian: Injekcije primijenite naizmjence na lijevu i desnu stranu donjeg dijela trbuha.
English: During treatment of VTE, concomitant therapy with vitamin K antagonist should be administered in accordance with the information of Section 4.5.
Croatian: Tijekom liječenja VTE, istodobno liječenje antagonistom vitamina K treba primijeniti u skladu s podacima u Poglavlju 4.5.
English: The effects on the incidence of MI and RI were not statistically different between the fondaparinux and enoxaparin treatment groups.
Croatian: Učinci na incidenciju infarkta miokarda ili refraktorne ishemije nisu bili statistički različiti između skupina liječenih fondaparinuksom i enoksaparinom.
English: In the Phase III study in STEMI patients, the most commonly reported non-bleeding adverse events (reported in at least 1% of subjects on fondaparinux) were atrial fibrillation, pyrexia, chest pain, headache, ventricular tachycardia, vomiting, and hypotension.
Croatian: U studiji faze III u bolesnika sa STEMI, najčešće prijavljene nuspojave koje nisu bile povezane s krvarenjem (prijavljene u najmanje 1% bolesnika na fondaparinuksu) bile su fibrilacija atrija, porast tjelesne temperature, bol u prsima, glavobolja, ventrikularna tahikardija, povraćanje i hipotenzija.
English: As renal function is generally decreasing with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2).
Croatian: Budući da bubrežna funkcija općenito opada s dobi, stariji bolesnici mogu imati smanjeno izlučivanje i povećanu izloženost fondaparinuksu (vidjeti dio 5.2).
English: There are two types of safety syringes used for Arixtra, designed to protect you from needle stick injuries following injection.
Croatian: Postoje dva tipa sigurnosnih štrcaljki koje se koriste s lijekom Arixtra, dizajniranih da Vas zaštite od slučajnog uboda iglom nakon injiciranja.
English: The first dose of fondaparinux is administered intravenously and subsequent doses are administered by subcutaneous injection.
Croatian: Prva doza fondaparinuksa primijenjuje se intravenski, a sljedeće doze supkutanom injekcijom.
English: In clinical studies performed with fondaparinux, oral anticoagulants (warfarin) did not interact with the pharmacokinetics of fondaparinux; at the 10 mg dose used in the interaction studies, fondaparinux did not influence the anticoagulation monitoring (INR) activity of warfarin.
Croatian: U kliničkim ispitivanjima s fondaparinuksom, oralni antikoagulansi (varfarin) nisu pokazali interakciju s farmakokinetikom fondaparinuksa; pri dozi od 10 mg koja se koristila u ispitivanjima interakcija, fondaparinuks nije utjecao na antikoagulacijsku aktivnost varfarina (INR).
English: Fondaparinux should be used with care in these patients.
Croatian: Fondaparinuks treba koristiti uz oprez u tih bolesnika.
English: • Prevention of VTE - Dosing adjustment of fondaparinux is not necessary.
Croatian: • Prevencija VTE - nije potrebna prilagodba doziranja fondaparinuksa.
English: If you stop the treatment before your doctor told you to, the blood clot may not be treated properly and you may also be at risk of developing a new blood clot in a vein of your leg or in the lung.
Croatian: Vam to preporuči liječnik, krvni ugrušak možda neće biti pravilno liječen, a može postojati i veći rizik od nastanka novog ugruška krvi u venama na nozi ili u plućima.
English: Patients who required thrombolysis or embolectomy or vena cava filter were excluded.
Croatian: Isključeni su bolesnici kojima je bila potrebna tromboliza, embolektomija ili uvođenje filtera u venu cavu.
English: Incidence
Croatian: Incidencija
English: For treatment of UA/NSTEMI and STEMI-Fondaparinux should be used with caution in patients who are being treated concomitantly with other agents that increase the risk of haemorrhage (such as GPIIb/IIIa inhibitors or thrombolytics).
Croatian: U liječenju UA/NSTEMI i STEMI - fondaparinuks treba koristiti uz oprez u bolesnika koji se istodobno liječe drugim agensima koji povećavaju rizik od krvarenja (kao što su inhibitori GP IIb/IIIa ili trombolitici).
English: Animal studies are insufficient with respect to effects on pregnancy, embryo/foetal development, parturition and postnatal development because of limited exposure.
Croatian: rezultati ispitivanja na životinjama o utjecaju na trudnoću, embriofetalni razvoj, porod i postnatalni razvoj nisu dovoljni.
English: • collapse.
Croatian: • kolaps
English: • swelling (oedema)
Croatian: • oticanje (edemi)
English: Gently pinch the skin that has been cleaned to make a fold.
Croatian: Očišćenu kožu nježno stisnite da nastane kožni nabor.
English: Bleeding was a commonly reported event in patients with UA/NSTEMI and STEMI.
Croatian: Krvarenje je često prijavljen događaj u bolesnika s UA/NSTEMI i STEMI.
English: • anxiety or confusion
Croatian: • tjeskoba ili smetenost
English: Arixtra syringe may contain latex
Croatian: Arixtra štrcaljka može sadržavati lateks
English: If you have kidney disease, the dose may be reduced to 1.5 mg once a day.
Croatian: Ako patite od bolesti bubrega, liječnik će Vam propisati manju dozu od 1,5 mg jednom na dan.
English: Other antiplatelet medicinal products (acetylsalicylic acid, dipyridamole, sulfinpyrazone, ticlopidine or clopidogrel), and NSAIDs should be used with caution.
Croatian: Ostale antitrombocitne lijekove (acetilsalicilnu kiselinu, dipiridamol, sulfinpirazon, tiklopidin ili klopidogrel) kao i nesteroidne antireumatike treba primjenjivati uz oprez.
English: The syringe needle shield contains latex.
Croatian: Štitnik za iglu sadrži lateks.
English: Fondaparinux does not bind to platelet factor 4 and does not cross-react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II.
Croatian: Fondaparinuks se ne veže na trombocitni faktor 4 i obično ne pokazuje križnu reakciju sa serumima bolesnika s trombocitopenijom induciranom heparinom (HIT) tipa II.
English: The recommended dose is 2.5 mg once a day, injected at about the same time each day.
Croatian: Preporučena doza je 2,5 mg jednom na dan, a treba je primijeniti otprilike u isto vrijeme svakog dana.
English: • leg pain or stomach pain
Croatian: • bol u nogama ili u trbuhu
English: The incidence of symptomatic DVT was similar between treatment groups: 6 patients (0.4%) in the fondaparinux group vs 5 patients (0.3%) in the dalteparin group.
Croatian: Incidencija simptomatskih DVT bila je slična u obje skupine: 6 bolesnika (0,4%) u skupini koja je dobivala fondaparinuks, u odnosu na 5 bolesnika (0,3%) u skupini na dalteparinu.
English: LIST OF EXCIPIENTS Also contains: sodium chloride, water for injections, hydrochloric acid, sodium hydroxide.
Croatian: Također sadrži: natrijev klorid, vodu za injekcije, kloridnu kiselinu, natrijev hidroksid.
English: The lower plasma concentrations of fondaparinux were attributed to reduced binding to ATIII secondary to the lower ATIII plasma concentrations in subjects with hepatic impairment thereby resulting in increased renal clearance of fondaparinux.
Croatian: Snižene koncentracije fondaparinuksa u plazmi pripisane su smanjenom vezivanju na ATIII, kao posljedici njegove snižene plazmatske koncentracije u bolesnika s jetrenim oštećenjem, što je rezultiralo povećanim bubrežnim klirensom fondaparinuksa.
English: A randomised, open-label, clinical trial was conducted in patients with acute symptomatic PE.
Croatian: Provedeno je randomizirano otvoreno kliničko ispitivanje u bolesnika s akutnim simptomima plućne embolije.
English: • Prevention of VTE and Treatment of UA/NSTEMI and STEMI - Dosing adjustment of fondaparinux is not necessary.
Croatian: • Prevencija VTE i liječenje UA/NSTEMI i STEMI - nije potrebna prilagodba doziranja fondaparinuksa.
English: Nervous system disorders Rare: anxiety, somnolence, vertigo, dizziness, headache, confusion
Croatian: Poremećaji živčanog sustava Rijetko: anksioznost, somnolencija, vrtoglavica, omaglica, glavobolja, konfuzija
English: Instruction on self-administration by subcutaneous injection is included in the Package Leaflet.
Croatian: Upute za samoinjiciranje supkutanom injekcijom navedene su u uputi o lijeku.
English: In superficial vein thrombosis patients who are to undergo surgery or other invasive procedures, fondaparinux, where possible, should not be given during the 24 hours before surgery.
Croatian: U bolesnika s trombozom površinske vene koji će se podvrgnuti operaciji ili nekom drugom invazivnom zahvatu, fondaparinuks, kada je to moguće, ne treba davati tijekom 24 sata prije zahvata.
English: The dose should be reduced to 1.5 mg once daily in patients with creatinine clearance in the range of 20 to 50 ml/min (see sections 4.4 and 5.2).
Croatian: Dozu treba smanjiti na 1,5 mg jedanput na dan u bolesnika s klirensom kreatinina od 20 do 50 ml/min (vidjeti dio 4.4 i 5.2).
English: Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
Croatian: Pri doziranju jednom na dan, stanje dinamičke ravnoteže razina u plazmi postiže se nakon 3-4 dana, uz porast Cmax i AUC od 1,3 puta.
English: Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adultsfor whom urgent (< 120 mins) invasive management (PCI) is not indicated (see sections 4.4 and 5.1).
Croatian: Liječenje nestabilne angine pektoris ili infarkta miokarda bez elevacije ST-segmenta (UA/NSTEMI) u odraslih osoba u kojih nije indicirano hitno (< 120 minuta) invazivno liječenje perkutanom koronarnom intervencijom (vidjeti dio 4.4 i 5.1).
English: STEP BY STEP GUIDE TO USING ARIXTRA
Croatian: VODIČ ZA PRIMJENU LIJEKA ARIXTRA PO KORACIMA
English: • prevent the formation of blood clots in the blood vessels of the legs or lungs after orthopaedic surgery (such as hip or knee surgery) or abdominal surgery
Croatian: • za sprječavanje stvaranja ugrušaka krvi u krvnim žilama nogu ili pluća nakon ortopedske operacije, npr. operacije kuka ili koljena, ili nakon operacije u trbušnoj šupljini
English: Below 50 kg
Croatian: Uobičajena doza manje od 50 kg
English: • Treatment of UA/NSTEMI and STEMI - For the treatment of UA/NSTEMI and STEMI, there are limited clinical data available on the use of fondaparinux 2.5mg once daily in patients with creatinine clearance between 20 and 30 ml/min.
Croatian: • Liječenje UA/NSTEMI i STEMI - dostupni su ograničeni klinički podaci o primjeni fondaparinuksa 2,5 mg jedanput na dan u bolesnika s klirensom kreatinina između 20 i 30 ml/min.
English: Contact your doctor or pharmacist before stopping.
Croatian: Posavjetujte se s liječnikom ili ljekarnikom prije prestanka primjene lijeka
English: In post marketing experience, rare cases of gastritis, constipation, diarrhoea and bilirubinaemia have been reported.
Croatian: Nakon stavljanja lijeka u promet prijavljeni su rijetki slučajevi gastritisa, konstipacije, proljeva i bilirubinemije.
English: Bleeding risk is increased with concomitant administration of fondaparinux and agents that may enhance the risk of haemorrhage (see section 4.4).
Croatian: Rizik od krvarenja povećava se istodobnom primjenom fondaparinuksa i lijekova koji mogu povećati rizik od krvarenja (vidjeti dio 4.4).
English: In patients ≥75 years, fondaparinux should be used with care, as renal function decreases with age (see section 4.4).
Croatian: U bolesnika starih ≥75 godina fondaparinuks treba koristiti uz oprez jer se bubrežna funkcija smanjuje s dobi (vidjeti dio 4.4).
English: One experienced hypertensive encephalopathy accompanied by intracranial bleeding on day 5 of therapy resulting in fondaparinux discontinuation.
Croatian: Jedan je bolesnik doživio hipertenzivnu encefalopatiju praćenu intrakranijalnim krvarenjem petog dana liječenja, što je rezultiralo prekidom primjene fondaparinuksa.
English: The pharmacokinetics of fondaparinux sodium are derived from fondaparinux plasma concentrations quantified via anti factor Xa activity.
Croatian: Farmakokinetika fondaparinuksnatrija izvedena je iz koncentracija fondaparinuksa u plazmi, kvantitativno izmjerenih putem aktivnosti anti-Xa.
English: The safety and efficacy of fondaparinux 2.5 mg has not been studied in the following groups: patients with superficial-vein thrombosis following sclerotherapy or resulting as a complication of an intravenous line, patients with history of superficial-vein thrombosis within the previous 3 months, patients with history of venous thromboembolic disease within the previous 6 months, or patients with active cancer (see section 4.2 and 5.1).
Croatian: Sigurnost i djelotvornost primjene fondaparinuksa od 2,5 mg nije bila ispitivana u sljedećim skupinama bolesnika: bolesnici s trombozom površinske vene nakon skleroterapije ili kao posljedicom postavljenog venskog puta, bolesnici s anamnezom tromboze površinske vene unutar posljednja 3 mjeseca, odnosno venske tromboembolije unutar posljednjih 6 mjeseci ili bolesnici s aktivnom malignom bolešću (vidjeti dio 4.2 i 5.1).
English: Following once daily subcutaneous dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in Cmax and AUC.
Croatian: Pri doziranju jednom na dan supkutano, stanje dinamičke ravnoteže razina u plazmi postiže se nakon 3 - 4 dana, uz porast Cmax i AUC od 1,3 puta.
English: Follow-up therapy with another anticoagulant medicinal product If follow-up treatment is to be initiated with heparin or LMWH, the first injection should, as a general rule, be given one day after the last fondaparinux injection.
Croatian: Ako je potrebno daljnje liječenje nastaviti heparinom ili niskomolekularnim heparinom, opće je pravilo da prvu injekciju treba dati jedan dan nakon posljednje injekcije fondaparinuksa.
English: • Prevention of VTE - Fondaparinux is known to be mainly excreted by the kidney.
Croatian: • Profilaksa VTE - Poznato je da se fondaparinuks najvećim dijelom izlučuje putem bubrega.
English: Oral absorption by the child is however unlikely.
Croatian: Međutim, malo je vjerojatno da bi kod dojenčeta moglo doći do peroralne apsorpcije.
English: In an open-label study, 24 paediatric patients (n=10, age 1 to ≤ 5 years weight range 8-20 kg; n=7, age 6 to ≤ 12 years weight range 17-47 kg and n=7 age 13 to ≤ 18 years weight range 47-130 kg) diagnosed with venous thrombosis at study entry were administered fondaparinux.
Croatian: do ≤5 godina, raspon TT 8 - 20 kg; n = 7, dob 6 do ≤12 godina, raspon TT 17 - 47 kg i n = 7, dob 13 do ≤18 godina, raspon TT 47 - 130 kg), kojima je dijagnosticirana venska tromboza na početku ispitivanja.
English: A randomised, double blind, clinical trial (CALISTO) included 3002 patients with acute symptomatic isolated, spontaneous superficial-vein thrombosis of the lower limbs, at least 5 cm long, confirmed by compression ultrasonography.
Croatian: Randomizirano, dvostruko-slijepo kliničko ispitivanje (CALISTO) uključilo je 3002 ispitanika s akutnom simptomatskom, izoliranom, spontano nastalom trombozom površne vene donjih ekstremiteta, u dužini barem 5 cm, a potvrđene kompresijskim ultrazvukom.
English: If co-administration is essential, close monitoring is necessary.
Croatian: Ako je istodobna primjena neophodna, potrebno je pažljivo pratiti bolesnika.
English: Treatment with fondaparinux was demonstrated to be non-inferior to unfractionated heparin (VTE rates 3.8% and 5.0%, respectively).
Croatian: Pokazalo se da liječenje fondaparinuksom nije bilo inferiorno nefrakcioniranom heparinu (stopa VTE 3,8% odnosno
English: Sites of administration should alternate between the left and the right anterolateral and left and right posterolateral abdominal wall.
Croatian: Injekciju treba naizmjenično aplicirati u lijevu i desnu anterolateralnu, te lijevu i desnu posterolateralnu trbušnu stijenku.
English: • Prophylaxis of VTE - Patients with creatinine clearance <50 ml/min are at increased risk of bleeding and VTE and should be treated with caution (see sections 4.2, 4.3 and 5.2).
Croatian: • Profilaksa VTE - Bolesnici s klirensom kreatinina <50 ml/min imaju povećan rizik od krvarenja i treba ih liječiti uz oprez (vidjeti dio 4.2, 4.3 i 5.2).
English: The incidence of each thromboembolic component of the primary outcome was also significantly reduced in fondaparinux patients as follows: symptomatic PE [0 (0%) vs 5 (0.3%) (p=0.031)], symptomatic DVT [3 (0.2%) vs 18 (1.2%); relative risk reduction 83.4% (p<0.001)], symptomatic superficial-vein thrombosis extension [4 (0.3%) vs 51 (3.4%); relative risk reduction 92.2% (p<0.001)], symptomatic superficial-vein thrombosis reoccurrence [5 (0.3%) vs 24 (1.6%); relative risk reduction 79.2% (p<0.001)].
Croatian: Incidencija svake tromboembolijske komponente primarnog ishoda je također značajno smanjena u fondaparinuks skupini bolesnika kako slijedi: simptomatska PE [0 (0%) vs 5 (0,3%) (p=0,031)], simptomatska DVT [3 (0,2%) naspram 18 (1,2%); relativna redukcija rizika od 83,4% (p<0,001)], simptomatsko proširenje (ekstenzija) tromboze površinske vene [4 (0,3%) vs 51 (3,4%); relativna redukcija rizika od 92,2% (p<0,001)], recidiv simptomatske tromboze površinske vene [5 (0,3%) vs 24 (1,6%); relativna redukcija rizika od 79,2% (p<0,001)].
English: Rare: hypotension
Croatian: Rijetko: hipotenzija
English: Picture D
Croatian: Slika D
English: Consequently, unbound concentrations of fondaparinux are expected to be unchanged in patients with mild to moderate hepatic impairment, and therefore, no dose adjustment is necessary based on pharmacokinetics.
Croatian: Posljedično se u bolesnika s blagim do umjerenim oštećenjem funkcije jetre ne očekuje promjena koncentracije slobodnog fondaparinuksa, te na temelju farmakokinetike nije potrebna prilagodba doze.
English: Patients with creatinine clearance <50 ml/min are at increased risk of bleeding and VTE and should be treated with caution (see sections 4.2, 4.3 and 5.2).
Croatian: Bolesnici s klirensom kreatinina <50 ml/min imaju povećan rizik od krvarenja i treba ih liječiti uz oprez (vidjeti dio 4.2, 4.3 i 5.2).
English: The incidences of adjudicated guiding catheter thrombus were 0.1% (1/1002) and 0.5% (5/1024), in patients randomised to “standard dose” and “low dose” UFH respectively during PCI.
Croatian: Incidencija tromboze u provodnom kateteru je bila 0,1% (1/1002) u bolesnika randomiziranih na “standardnu dozu” UFH, odnosno 0,5% (5/1024) u bolesnika randomiziranih na “nisku dozu” UFH tijekom PCI.
English: In patients with severe hepatic impairment, fondaparinux should be used with care as this patient group has not been studied (see sections 4.4 and 5.2).
Croatian: U bolesnika s teškim oštećenjem jetre fondaparinuks treba koristiti uz oprez, jer njegova primjena u toj skupini bolesnika nije ispitivana (vidjeti dio 4.4 i 5.2).
English: (2) Npn stands for non-protein-nitrogen such as urea, uric acid, amino acid, etc.
Croatian: (1) nisu uzete u obzir pojedinačne nuspojave, osim medicinski relevantnih (2) Npn označava neproteinski dušik, npr. ureu, mokraćnu kiselinu, aminokiseline itd.
English: Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (see sections 4.2 and 5.1).
Croatian: Liječenje odraslih osoba s akutnom spontanom i simptomatskom površinskom venskom trombozom donjih ekstremiteta bez prateće duboke venske tromboze (vidjeti dio 4.2 i 5.1).